Gerresheimer AG (GRRMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Gerresheimer AG (GRRMF) trades at $30.73 with AI Score 43/100 (Grade C). Gerresheimer AG is a global manufacturer of packaging products and drug delivery devices, operating through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. Market cap: $1.06B, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for GRRMF: GRRMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates GRRMF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
GRRMF: the 1 perspectives are evenly split.
How is this calculated? →Gerresheimer AG (GRRMF) Healthcare & Pipeline Overview
Gerresheimer AG manufactures specialized packaging solutions and drug delivery systems for the healthcare industry, focusing on plastics, glass, and advanced technologies. With a global presence and a history dating back to 1864, the company serves pharmaceutical, biotech, and cosmetic sectors with a diverse product portfolio.
What Is the Investment Thesis for GRRMF?
Gerresheimer AG presents an investment opportunity within the healthcare sector, driven by its diverse product portfolio and global presence. The company's focus on drug delivery systems and specialized packaging caters to the growing demand for advanced healthcare solutions. With a market capitalization of $1.06B and a P/E ratio of 26.14, Gerresheimer exhibits a moderate valuation. Key growth catalysts include the expansion of its Advanced Technologies division and increasing demand for injectable drugs. However, investors may want to evaluate the company's relatively low profit margin of 1.0% and potential risks associated with regulatory changes and competition. The dividend yield is 0.23%.
Based on FMP financials and quantitative analysis
GRRMF Key Highlights
- Market capitalization of $1.06B indicates a mid-sized player in the medical instruments and supplies market.
- P/E ratio of 26.14 suggests a moderate valuation compared to its earnings.
- Profit margin of 1.0% reflects a need for improved operational efficiency.
- Gross margin of 26.9% indicates the profitability of its products before operating expenses.
- Dividend yield of 0.23% provides a modest income stream for investors.
Who Are GRRMF's Competitors?
GRRMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BOEUF Bonesupport Holding AB (publ) | $21.40 | +0.00% | $1.41B | 51 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| EKTAF Elekta AB (publ) | $5.04 | +0.00% | $1.85B | 47 |
| EKTAY Elekta AB (publ) | $5.29 | +2.52% | $2.02B | 47 |
| GENSF Genus plc | $31.07 | +0.00% | $2.06B | 52 |
| NYXH Nyxoah S.A. | $1.72 | -3.37% | $68.12M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $26.98 | +2.66% | $1.57B | 67 |
| ZTEK Zentek Ltd. | $0.45 | -3.63% | $48.50M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are GRRMF's Key Strengths?
- Global presence and established reputation in the healthcare industry.
- Diverse product portfolio spanning packaging, drug delivery systems, and advanced technologies.
- Long-standing relationships with major pharmaceutical companies.
- Expertise in regulatory compliance and quality control.
What Are GRRMF's Weaknesses?
- Relatively low profit margin compared to industry peers.
- Dependence on the pharmaceutical industry, making it susceptible to regulatory changes.
- Limited brand recognition among consumers.
- Exposure to currency fluctuations due to its global operations.
What Could Drive GRRMF Stock Higher?
- Expansion of the Advanced Technologies division with new product launches in micro pumps and smart drug delivery systems.
- Increasing demand for injectable drugs driving growth in the Plastics & Devices division.
- Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Potential regulatory approvals for new drug delivery devices in key markets.
- Focus on sustainable packaging solutions attracting environmentally conscious customers.
What Are the Key Risks for GRRMF?
- Financial-distress signal — its Altman Z-Score of 0.96 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-1.0%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established players and new entrants in the healthcare packaging market.
- Stringent regulatory requirements and potential product recalls affecting product sales and reputation.
- Economic downturns affecting healthcare spending and demand for pharmaceutical products.
- Exposure to currency fluctuations due to its global operations.
- Relatively low profit margin compared to industry peers, requiring improved operational efficiency.
What Are the Growth Opportunities for GRRMF?
- Expansion of Advanced Technologies Division: Gerresheimer's Advanced Technologies division, which develops smart drug delivery systems like micro pumps, represents a significant growth opportunity. The market for advanced drug delivery systems is projected to reach $24.7 billion by 2027, driven by the increasing demand for personalized medicine and self-administration options. By focusing on innovative solutions for chronic diseases like Parkinson's and heart failure, Gerresheimer can capture a larger share of this expanding market. Timeline: Ongoing.
- Increasing Demand for Injectable Drugs: The rising prevalence of chronic diseases and the growing biologics market are driving increased demand for injectable drugs, creating a significant opportunity for Gerresheimer's Plastics & Devices division. The global injectable drug market is expected to reach $790.7 billion by 2030. Gerresheimer's expertise in manufacturing prefillable syringes and other injectable drug delivery systems positions it well to capitalize on this trend. Timeline: Ongoing.
- Growth in Emerging Markets: Emerging markets, with their rapidly growing populations and increasing healthcare expenditure, present a substantial growth opportunity for Gerresheimer. These markets are experiencing a rising demand for pharmaceutical packaging and drug delivery systems. By expanding its presence in regions like Asia-Pacific and Latin America, Gerresheimer can tap into new revenue streams and diversify its geographic footprint. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Gerresheimer can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. Collaborating with pharmaceutical companies and biotech firms can facilitate the development of innovative drug delivery solutions and secure long-term supply contracts. Acquisitions of complementary businesses can provide access to new markets and technologies. Timeline: Ongoing.
- Focus on Sustainable Packaging Solutions: With increasing environmental awareness, there is a growing demand for sustainable packaging solutions in the healthcare industry. Gerresheimer can capitalize on this trend by developing and offering eco-friendly packaging options, such as recyclable plastics and bio-based materials. By positioning itself as a leader in sustainable packaging, Gerresheimer can attract environmentally conscious customers and gain a competitive advantage. Timeline: Ongoing.
What Opportunities Does GRRMF Have?
- Expanding into emerging markets with growing healthcare expenditure.
- Developing innovative drug delivery systems for chronic diseases.
- Acquiring complementary businesses to expand its product portfolio.
- Capitalizing on the increasing demand for sustainable packaging solutions.
What Threats Does GRRMF Face?
- Intense competition from established players and new entrants.
- Stringent regulatory requirements and potential product recalls.
- Economic downturns affecting healthcare spending.
- Disruptive technologies that could render existing products obsolete.
What Are GRRMF's Competitive Advantages?
- Specialized Expertise: Gerresheimer's deep expertise in manufacturing specialized packaging and drug delivery systems creates a barrier to entry for new competitors.
- Long-Term Relationships: The company's long-standing relationships with pharmaceutical companies and biotech firms provide a stable revenue stream and a competitive advantage.
- Regulatory Compliance: Gerresheimer's adherence to stringent regulatory requirements in the healthcare industry ensures product quality and safety, building trust with customers.
- Global Footprint: The company's global manufacturing and distribution network allows it to serve customers in both established and emerging markets.
What Does GRRMF Do?
Founded in 1864 and headquartered in Düsseldorf, Germany, Gerresheimer AG has evolved into a leading global manufacturer of packaging products and drug delivery devices. The company operates through three primary divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers a range of drug delivery systems, including inhalers, insulin pen systems, and prefillable syringes, along with diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries. This division also provides containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications, as well as bottles and containers for nutritional supplements. The Primary Packaging Glass division focuses on glass primary packaging for the pharma and cosmetics industries, producing infusion, dropper, and syrup bottles, injection vials, ampoules, and cartridges. Additionally, it offers miniature bottles and glass containers for liquid food, spices, and spirits, along with packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division is dedicated to developing smart drug delivery systems, such as micro pumps, which are used to self-administer medication for conditions like Parkinson's disease or heart failure. Gerresheimer serves a diverse customer base across the pharmaceutical, biotech, diagnostics, medical technology, and cosmetics industries, with a global footprint that allows it to cater to both established and emerging markets.
What Products and Services Does GRRMF Offer?
- Manufactures plastic containers and closures for liquid and solid pharmaceuticals.
- Produces glass vials, ampoules, and cartridges for injectable drugs.
- Develops and manufactures drug delivery systems, including inhalers and pen systems.
- Offers packaging solutions for the cosmetics and personal care industries.
- Creates advanced micro pumps for self-administration of medication.
- Provides diagnostic systems for the pharma and biotech sectors.
How Does GRRMF Make Money?
- Manufacturing and selling primary packaging glass for pharmaceutical and cosmetic products.
- Producing plastic containers and drug delivery systems for the healthcare industry.
- Developing and commercializing advanced drug delivery technologies.
- Generating revenue through long-term supply contracts with pharmaceutical companies.
What Industry Does GRRMF Operate In?
Gerresheimer AG operates in the medical instruments and supplies industry, which is characterized by continuous innovation and stringent regulatory requirements. The market is driven by increasing healthcare expenditure, an aging population, and the rising prevalence of chronic diseases. The competitive landscape includes companies like BOEUF, EBOSY, EKTAF, EKTAY, and GENSF, each vying for market share through product differentiation and strategic partnerships. Trends such as personalized medicine and the growing demand for self-administered drug delivery systems are shaping the industry's future.
Who Are GRRMF's Key Customers?
- Pharmaceutical companies requiring primary packaging for drugs.
- Biotech firms needing drug delivery systems for injectable medications.
- Cosmetics companies seeking packaging solutions for beauty products.
- Healthcare providers using diagnostic systems and drug delivery devices.
FY2026 estForward Outlook
Wall Street analysts project Gerresheimer AG revenue of about $2.29B for fiscal 2026, with EPS near $2.16. The estimate reflects 9 contributing analysts.
F-Score 5/9Financial Health
Gerresheimer AG's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.96 places it in the distress zone, a signal of elevated financial risk.
ROE -1%Key Financial Metrics
Return on equity for Gerresheimer AG stands at -1.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.81 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -1.4%, the inverse of the P/E and a quick read on earnings relative to price.
Gerresheimer AG (GRRMF) Valuation Context
Valued at $1.06B, GRRMF is classified as a small-cap stock. Relative to its peer group, GRRMF's quantitative score of 43/100 is roughly in line with the peer average of 48/100.
Company Profile
Gerresheimer AG operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Düsseldorf, DE. The company is led by CEO Uwe Ferdinand Röehrhoff. GRRMF has traded publicly since 2009.
GRRMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity suggests confidence in the company's future, indicating that those closest to the business believe in its growth potential.
- Community sentiment has shifted positively, with discussions highlighting Gerresheimer's strong position in the healthcare packaging sector, which remains resilient amid economic uncertainties.
- There is increasing demand for medical glass and plastic products, positioning Gerresheimer well to capitalize on the ongoing healthcare trends.
- Market perception has improved as the company has made strategic partnerships that enhance its innovation capabilities, fostering optimism among investors.
Bear Case
- Concerns about supply chain disruptions continue to loom, which could impact production timelines and operational efficiency for Gerresheimer.
- Despite positive sentiment, some community voices express skepticism regarding the company's ability to maintain profitability amidst rising raw material costs.
- Recent developments in regulatory environments may pose challenges, creating uncertainty around compliance and operational adjustments for Gerresheimer.
- While insider buying is a positive sign, it may not fully offset the cautious outlook from analysts regarding broader market conditions affecting the healthcare sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
GRRMF Latest News
-
Assessing Gerresheimer (XTRA:GXI) Valuation After Volatile Share Moves And The Bormioli Pharma Acquisition
Yahoo! Finance: GRRMF News · Jun 5, 2026
-
Newel Health and Gerresheimer Launch Strategic Collaboration to Support Pharma Companies in the Era of Integrated Digital Therapies
Yahoo! Finance: GRRMF News · May 27, 2026
-
Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed
Yahoo! Finance: GRRMF News · May 18, 2026
-
Prefilled Syringes Market Global Forecast Report 2026-2031: Growing Preference for Unit-Dose Medication Using Prefilled Syringes / Emerging Markets with Growing Healthcare Infrastructure
Yahoo! Finance: GRRMF News · May 11, 2026
GRRMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for GRRMF.
Price Targets
Wall Street price target analysis for GRRMF.
GRRMF MoonshotScore
What does this score mean?
The MoonshotScore rates GRRMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Assessing Gerresheimer (XTRA:GXI) Valuation After Volatile Share Moves And The Bormioli Pharma Acquisition
Newel Health and Gerresheimer Launch Strategic Collaboration to Support Pharma Companies in the Era of Integrated Digital Therapies
Middle East and Africa Wearable Injectors Market Trends and Forecast Report 2026-2035 Featuring Amgen, BD, Biocon, Gerresheimer, Insulet, J&J, Medtronic, Roche, West Pharmaceutical, Ypsomed
Prefilled Syringes Market Global Forecast Report 2026-2031: Growing Preference for Unit-Dose Medication Using Prefilled Syringes / Emerging Markets with Growing Healthcare Infrastructure
Leadership: Uwe Ferdinand Röehrhoff
CEO
Uwe Ferdinand Röehrhoff has served as the CEO of Gerresheimer AG, managing a workforce of 13,632 employees. His background includes extensive experience in the pharmaceutical and healthcare industries. He has held various leadership positions in multinational corporations, focusing on strategic planning, operational excellence, and business development. Röehrhoff's expertise spans across multiple functional areas, including manufacturing, supply chain management, and sales and marketing. His academic credentials include advanced degrees in engineering and business administration.
Track Record: Under Uwe Ferdinand Röehrhoff's leadership, Gerresheimer AG has focused on expanding its global footprint and strengthening its position as a leading provider of packaging solutions and drug delivery systems. Key achievements include the successful integration of strategic acquisitions, the implementation of operational efficiency initiatives, and the development of innovative products for the healthcare industry. The company has also made significant investments in research and development to drive future growth.
GRRMF OTC Market Information
The OTC Other tier, where Gerresheimer AG (GRRMF) trades, represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited reporting requirements and may not meet the minimum financial standards required for exchange listing. This tier typically includes companies with limited operating history, penny stocks, and those facing financial distress. Investing in OTC Other stocks carries significantly higher risks compared to exchange-listed securities due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Disclosure: The lack of comprehensive and readily available financial information increases the risk of investing in GRRMF.
- Low Liquidity: Limited trading volume can make it difficult to buy or sell shares without affecting the price.
- Price Volatility: OTC stocks are often subject to greater price swings due to lower trading volumes and potential for manipulation.
- Regulatory Scrutiny: OTC-listed companies may face increased regulatory scrutiny and potential delisting.
- Information Asymmetry: The limited availability of information can create an uneven playing field for investors.
- Verify the company's financial statements through independent sources.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Evaluate the company's corporate governance practices.
- Monitor news and regulatory filings related to the company.
- Consult with a financial advisor before making any investment decisions.
- Established Operations: Gerresheimer AG has a long operating history dating back to 1864, suggesting a degree of stability and experience.
- Global Presence: The company's global manufacturing and distribution network indicates a significant scale of operations.
- Industry Recognition: Gerresheimer AG is a recognized player in the healthcare packaging and drug delivery systems market.
- Customer Base: The company serves major pharmaceutical companies and biotech firms, indicating a level of trust and credibility.
- Management Team: The presence of an experienced CEO, Uwe Ferdinand Röehrhoff, suggests capable leadership.
GRRMF Healthcare Stock FAQ
What does Gerresheimer AG do?
Gerresheimer AG is a global manufacturer of packaging products and drug delivery devices, primarily serving the pharmaceutical, biotech, diagnostics, and medical technology industries. The company operates through three divisions: Plastics & Devices, which offers drug delivery systems and containers; Primary Packaging Glass, which provides glass packaging for pharma and cosmetics; and Advanced Technologies, which develops smart drug delivery systems. Gerresheimer's products are essential for the safe and effective delivery of medications and healthcare products worldwide.
What are the main risks for GRRMF?
The main risks for Gerresheimer AG include intense competition in the healthcare packaging market, stringent regulatory requirements and potential product recalls, economic downturns affecting healthcare spending, exposure to currency fluctuations, and a relatively low profit margin. The company's dependence on the pharmaceutical industry also makes it susceptible to regulatory changes and pricing pressures. Investors should carefully consider these risks before investing in GRRMF.
What are the key factors to evaluate for GRRMF?
Gerresheimer AG (GRRMF) holds an AI score of 43/100 (low). Not financial advice.
How frequently does GRRMF data refresh on this page?
GRRMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven GRRMF's recent stock price performance?
Gerresheimer AG (GRRMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global presence and established reputation in the healthcare industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRRMF overvalued or undervalued right now?
Valuing Gerresheimer AG (GRRMF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying GRRMF?
Before investing in Gerresheimer AG (GRRMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding GRRMF to a portfolio?
Key strength of Gerresheimer AG (GRRMF): Global presence and established reputation in the healthcare industry. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be delayed or incomplete due to OTC listing.
- AI analysis pending for GRRMF.